Table 1 Patient demographic and pathologic characteristics.
Case no. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age | 45 | 57 | 64 | 38 | 51 | 44 | 46 | 38 | 59 | 48 | 56 | 66 | 66 | 67 | 50 | 56 | 53.2 (mean) |
Gender | F | F | M | M | F | F | F | F | F | M | M | M | F | F | F | F | 5:11 (M:F) |
Morphology | |||||||||||||||||
Diffuse growth (%) | 100 | >75 | >75 | 100 | 100 | >75 | >75 | >75 | 75 | >75 | >75 | >75 | 100 | >75 | 100 | ~75 | 75–100% |
Micro-follicles | − | + | + | − | − | + | + | − | + | − | + | − | − | + | − | − | 43.7% |
Sclerosis | − | + | + | − | + | + | + | − | − | + | + | + | − | − | + | − | 56.2% |
Entrapped normal LN | + | + | − | − | − | + | + | + | − | − | − | + | − | − | − | − | 37.5% |
Nuclear contour | R | C | C | C | R | R&C | C | C | R | R | C | R&C | R | C | R | C | 5:4 (C:R) |
Immunophenotype | |||||||||||||||||
CD10 | + | + | + | + | + | + | +(P) | + | +(P)/W | + | + | + | + | + | + | + | 100.0% |
BCL6 | + | + | + | +(Fo) | NA | + | +(P) | +(Fo) | +(WP) | +(W) | + | + | + | + | + | NA | 100.0% |
BCL2 | + | +(V) | + | + | + | +(W)/E | E | E | +/− | + | + | + | + | + | − | + | 81.2% |
CD23 | +(P) | + | + | + | + | +(WP) | +(P) | +(Fo) | +/− | +(Fo) | + | + | + | +(W) | + | + | 100.0% |
FDC network | − | − | NA | − | − | − | Fo | Fo | − | − | Fo | − | − | Fo | − | Fo W | 31.2% |
Ki-67 proliferation (%) | <30 | 30–40 | 10 | <10 | NA | NA | 20 | NA | <10 | 10–20 | NA | 20–30 | NA | 10–20 | NA | 10–20 | 15–20% (mean) |
